The availability of large biobanks linked to electronic health records have enabled the identification of a growing number of genetic risk variants for alcohol use disorder (AUD). The genetic findings have begun to converge with the results of controlled trials of medications to treat AUD.
In this presentation, I will review findings from genome-wide association studies of alcohol-related traits and recent studies of topiramate, a medication that consistently and robustly reduces heavy drinking in patients with AUD.
This will include a recent preliminary analysis showing that topiramate’s effect on heavy drinking is moderated by polygenic risk for problematic alcohol use.
About Henry R Kranzler
Henry R Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania in Philadelphia.
Trained as a physician, psychiatrist, and clinical investigator, Dr Kranzler’s research on the molecular genetics of alcohol and drug use disorders and their precision pharmacological treatment has been supported since 1987 by grants from the U.S. National Institutes of Health.
He has authored more than 500 journal articles and 100 book chapters and edited nine books. Since 2014, Dr Kranzler has served as the Editor of Alcoholism: Clinical and Experimental Research, the official journal of the International Society of Biomedical Research on Alcoholism and the Research Society on Alcoholism.
|Date||Tuesday, 1 November 2022|
|Time||3:00pm - 4:00pm|
|Audience||Public,Undergraduate students,Postgraduate students,Staff|
|Location||William James Building Room 2.03, Dunedi|
|Contact Name||Narun Pat|
|Contact Phone||+64 3 4797645|